Biogen Idec Inc (BIIB.O)

BIIB.O on Nasdaq

412.79USD
3 Mar 2015
Change (% chg)

$-3.00 (-0.72%)
Prev Close
$415.79
Open
$415.00
Day's High
$415.17
Day's Low
$407.12
Volume
1,236,017
Avg. Vol
1,723,187
52-wk High
$416.82
52-wk Low
$272.02

BIIB.O

Chart for BIIB.O

About

Biogen Idec Inc. is a global biotechnology company. The Company discovers, develops, manufactures and markets therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. The Company’s products include AVONEX, TYSABRI, FAMPYRA, FUMADERM and RITUXAN. AVONEX is prescribed treatments for relapsing... (more)

Overall

Beta: 1.02
Market Cap(Mil.): $95,943.24
Shares Outstanding(Mil.): 234.61
Dividend: --
Yield (%): --

Financials

  BIIB.O Industry Sector
P/E (TTM): 33.03 38.99 40.21
EPS (TTM): 12.38 -- --
ROI: 26.64 17.01 16.34
ROE: 30.21 17.53 17.27
Search Stocks

Biogen forecasts 2015 earnings well ahead of Street view

- Biogen Idec Inc on Thursday reported fourth-quarter profit and issued a 2015 earnings forecast that both sailed past Wall Street estimates, driven by strong sales of its oral multiple sclerosis drug Tecfidera, sending shares more than 7 percent higher.

29 Jan 2015

Biogen forecasts 2015 earnings well ahead of Street view

Jan 29 - Biogen Idec Inc on Thursday reported higher-than-expected fourth-quarter profit on strong demand for its oral multiple sclerosis drug Tecfidera and issued a forecast for 2015 earnings far higher than Wall Street forecasts.

29 Jan 2015

Biogen to buy private U.K. company with chronic pain drug

- Biogen Idec Inc on Sunday said it would buy small, privately-held Convergence Pharmaceuticals to acquire the U.K.-based company's portfolio of experimental drugs for chronic nerve pain.

11 Jan 2015

Biogen to buy private U.K. company with chronic pain drug

Jan 11 - Biogen Idec Inc on Sunday said it would buy small, privately-held Convergence Pharmaceuticals to acquire the U.K.-based company's portfolio of experimental drugs for chronic nerve pain.

11 Jan 2015

Biogen shares fall after optic nerve study results seen as mixed

- Biogen Idec Inc said an experimental drug showed evidence of biological repair of the optic nerve in patients with acute inflammation of the optic nerve, but shares fell as analysts wondered how promising the mid-stage study results were.

08 Jan 2015

UPDATE 2-Biogen experimental drug shows evidence of optic nerve repair

Jan 8 - An experimental drug from Biogen Idec Inc showed evidence of biological repair of the optic nerve in a mid-stage study in patients with acute optic neuritis, an inflammation of the optic nerve that can lead to vision loss.

08 Jan 2015

Biogen says mid-stage optic nerve treatment study succeeds

Jan 8 - Biogen Idec Inc said on Thursday a mid-stage study of a new treatment for acute optic neuritis, an inflammation of the optic nerve that can lead to complete or partial loss of vision, showed evidence of biological repair of the visual system.

08 Jan 2015

India Morning Call-Global Markets

NEW YORK - U.S. stocks rose on Tuesday as energy stocks led the S&P 500 and Dow, while Biogen's rally on news about an experimental treatment for Alzheimer's disease topped gains at the Nasdaq.

02 Dec 2014

US STOCKS-Energy shares lead Wall St higher; telecoms slip

* More cars and trucks sold in November than analysts expected

02 Dec 2014

US STOCKS-Energy shares lead Wall St higher in broad advance

* More cars and trucks sold in November than analysts expected

02 Dec 2014

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: GlobalData
$125.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks